Behçet's disease: A dentist's overview

Clinical and Experimental Rheumatology

Volumn 26, Issue 4 SUPPL. 50, 2008, Pages

  Mumcu, Gonca ^a,b  

^a MARMARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Beh et's disease; Dentistry; Oral environment; Oral ulcers; Treatment

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; AZITHROMYCIN; BENZATHINE PENICILLIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 65; HLA B51 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MINOCYCLINE; SUCRALFATE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BACTERIAL COLONIZATION; BEHCET DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DENTAL CARE; DENTIST; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MEGADOSE; HEALTH; HEREDITY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; MOUTH HYGIENE; MOUTH ULCER; PATHOGENESIS; PERIODONTITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS; TOOTH BRUSHING;

BEHCET SYNDROME; DENTAL PROPHYLAXIS; HUMANS; ORAL ULCER; SALIVA;

EID: 55049122498     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. DIRESKENELI H: Behçet's disease: Infectious etiology, new autoantigens and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002.
2. GÜL A: Behçet's disease: An update on the pathogenesis. Clin Exp Rheumatol 2001; 19 (Suppl. 24): S6-S12.
3. YAZICI H: Behçet's syndrome. Curr Opin Rheumatol 1999; 11: 53-7.
4. BARNES G, YAZICI H: Behçet's disease. Rheumatology 1999; 38: 1171-6.
5. INTERNATIONAL STUDY GROUP FOR BEHCET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
6. ISOGAI E, OHNO S, KOTAKE S et al.: Chemiluminescence of neutrophils from patients with Behçet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990; 35: 43-8.
7. YOSHIKAWA K, KOTAKE S, SASAMOTO Y, OHNO S, MATSUDA H: Close association of Streptococcus sanguis and Behçet's disease. Nippon Ganka Gakkai Zasshi 1991; 95: 1261-7.
8. MIZUSHIMA Y: Behçet's Disease Research Committee of Japan, Skin hypersensitivity of streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease. J Rheumatol 1989; 16: 506-11.
9. MIZUSHIMA Y, MATSUDA T, HOSHL K, OHNO S: Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15: 1029-30.
10. KANEKO F, TOJO M, SATO M, ISOGAI E: The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med Biol 2003; 528: 181-3.
11. KANEKO F, OYAMA N, NISHIBU A: Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997; 38; 444-54.
12. ISOGAI E: Role of Streptococcus sanguis and traumatic factors in Behçet's disease. J Appl Res 2003; 3: 64-75.
13. KANEKO F, OYAMA N, YANAGIHORI H et al.: Role of oral streptococci in the pathogenesis of Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-16.
14. CALGUNERI M, ERTENLI I, KIRAZ S, ERMAN M, CELIK I: Effect of prophylactic benzathine penicilline on mucocutaneous sysmptoms of Behçet's disease. Dermatology 1996; 192: 125-8.
15. MUMCU G, ERGUN T, ELBIR Y et al.: Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005; 34: 13-6.
16. CALGUNERI M, KIRAZ S, ERTENLI I, BENEKLI M, KARAARSLAN Y, CELIK I: The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. Arthritis Rheum 1996; 39: 2062-5.
17. MUMCU G, INANC N, ELBIR Y, ERGUN T, YAVUZ S, DIRESKENELI H: Low serum mannose binding lectin levels predispose to S. mutans colonization in Behçet's disease. Clin Exp Rheumatol 2004; 22 (Suppl. 34): S-93.
18. MUMCU G, INANC N, YAVUZ S, DIRESKENELI H: The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease - Review. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S27-33.
19. MEALEY B, KLOKKEVOLD P: Clinical periodontology, in Periodontal Medicine, 9th ed., W.B. Saunders, Philadelphia, 2002; 229-52.
20. TONETTI M, D'IUTO F, NIBALI L et al.: Treatment of periodontitis and endothelial function. N Engl J Med 2007; 356: 911-20.
21. MEURMAN JH, SANSZ M, JANKET SJ: Oral health, aterosclerosis and cardiovascular disease. Crit Rev Oral Med 2004; 15: 403-13.
22. SODER PO, SODER B, NOWAK J, JOGESTRAND T: Early carotid atherosclerosis in subjects with periodontal diseases. Stroke 2005; 36: 1195-200.
23. PASCUAL-RAMOS V, HERNANDEZ-HERNANDEZ C, SOTO-ROJAS AE, CELIS-AGUILAR E, SANCHEZ-GUERRERO J: Association between dental caries and pneumonia in patients with systemic lupus erythematosus. J Rheumatol 2006; 33: 1996-2002.
24. MUMCU G, ERGUN T, INANC N et al.: Oral health is impaired in Behçet's disease and is associated with disease severity. Rheumatology 2004; 43: 1028-33.
25. CELENLIGIL-NAZLIEL H, KANSU E, EBERSOLE J: Periodontal findings and systemic antibody responses to oral microorganisms in Behçet's disease. J Periodontol 1999; 70: 1449-56.
26. CARL W, HAVENS J, KIELICH CDT: Behçet's disease: Dental and oral soft tissue complications. Quint Int 2000; 31: 113-6.
27. AKMAN A, KACAROGLU H, DONMEZ L, BACANLI A, ALPSOY E: Relationship between periodontal findings and Behçet's disease: A controlled study. J Clin Periodontol 2007; 34: 485-91.
28. AKMAN A, EKINCI NC, KACAROGLU H, YAVUZER U, ALPSOY E, YEGIN O: Relationship between periodontal findings and specific polymorphisims of interleukin-1 alpha and -1 beta in Turkish patients with Behçet's disease. Arch Dermatol Res 2008; 300: 19-26.
29. KARACAYLI U, MUMCU G, SIMSEK I et al.: Oral ulcer activation after dental and periodontal treatments in Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-36.
30. ANDERSEN RM, DAVIDSON PL: Ethnicity, Aging and oral health outcomes: a conceptual framework. Adv Dent Res 1997; 11: 203-9.
31. MUMCU G, STEWARD J, HAGI-PAVLI E et al.: Oral health and quality of life status in patients from the UK and Turkey: A comparative study in Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-5.
32. DALE BA, TAO R, KIMBALL JR, JUREVIC RJ: Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006; (Suppl. 1): S1-S13.
33. MCLACH JL, SLOAN A, SMITH AJ, LANDINI G, COOPER PR: S100 and cytokine expression in caries. Infect Immun 2004; 72: 4102-8.
34. FOELL D, WITTKOWSKI H, VOGL T, ROTH J: S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
35. HAGI-PAVLI E, PLEQUEZEULOS O, SEOUDI E et al.: Expression of epidermal growth factor receptor and its ligands in the oral cavity of Behçet's disease patients. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-9.
36. STEWART J, MUMCU G, HAQUE A et al.: Different cytokine expression by PBMC's of Behçet's patients: Influence of serum and saliva. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-9.
37. YURDAKUL S, MAT C, TUZUN Y et al.: A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001; 44: 2686-92.
38. HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide in the treatment of mucocutaneous lesions of Behçet's syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
39. HATEMI G, SILMAN A, DANG B et al.: Management of Behçet's disease: A systemic literature review for the EULAR evidence-based recommendations for the management of Behçet's disease. Ann Rheum Dis 2008; April 17.
40. MUMCU G, INANC N, ERGUN T, DIRESKENELI H: The effects of colchicine treatment on oral health in Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-34.
41. ALPSOY E, ER H, DURUSOY C, YILMAZ E: The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet's disease: a randomized, placebo-controlled. double-blind study. Arch Dermatol 1999; 135: 529-32.
42. TASLI L, MAT C, DESIMONE C, YAZICI H: Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol 2006; 24 (Suppl. 42): S83-S86.
43. BACANLI A, YEREBAKAN O, PARMAKSIZOGLU B, YILMAZ E, ALPSOY E: Topical granulocyte colony-stimulating factor for the treatment of oral and genital ulcers of patients with Behçet's disease. J Eur Acad Dermatol Venereol 2006; 20: 931-5.
44. BHAKTA BB, BRENNAN P, JAMES TE, CHAMBERLAIN A, NOBLE BA, SILMAN A: Behçet's disease: Evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-31.
45. LAWTON G, BHAKTA BB, CHAMBERLAIN A, TENNANT A: The Behçet's disease activity index. Rheumatology 2004; 43: 73-8.
46. YACIZI H, TUZUN Y, PAZARLI H et al.: Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 793-9.
47. FRESKO I, SOY M, HAMURYUDAN V et al.: Genetic anticipation in Behçet's sysndrome. Ann Rheum Dis 1998; 57: 45-8.
48. MUMCU G, INANC N, ERGUN T, DIRESKENELI H: A composite index for oral ulcer activity in Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S-35.
49. MUMCU G, HAYRAN O, OZALP DO et al.: The assessment of oral health-related quality of life by factor analysis in patients with Behçet's disease and recurrent apthous stomatitis. J Oral Pathol Med 2007; 36; 147-52.
50. MUMCU G, INANC N, ERGUN T et al.: Oral health-related quality of life is affected by disease activity in Behçet's disease. Oral Dis 2006; 12: 145-51.